Unlocking Opportunities with NGS for Critical Quality Attribute Measurement of Gene Therapy Products

September 1, 2022

In the race to make life-changing gene therapies more accessible, maintaining in-process critical quality attributes (CQAs) remains necessary to guarantee the delivery of safe and effective treatment. CQAs such as Identity, Potency, and Safety, can be efficiently monitored by implementing Next-Generation Sequencing (NGS) at various stages of development and manufacturing.  

Download this poster to learn how the NGS-based workflows of Genedata Selector^® eliminate the need for implementing multiple different assays to determine CQAs and discover:

• How our technology agnostic platform supports all types of NGS-based assays throughout the GT vector development process 
• How the platform's wizard-based Playbooks simplify and automate NGS-based assays for GT development 
• How the platform enables data traceability for all analyses and report generation for internal and external audits
• How the platform facilitates integrity analysis and provides clear go/no-go thresholds for faster and better-informed decisions